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Ubiquitin-like modifier FAT10 
attenuates RIG-I mediated antiviral 
signaling by segregating activated 
RIG-I from its signaling platform
Nhung T.H. Nguyen*, Hesung Now*, Woo-Jong Kim, Nari Kim & Joo-Yeon Yoo
RIG-I is a key cytosolic RNA sensor that mediates innate immune defense against RNA virus. Aberrant 
RIG-I activity leads to severe pathological states such as autosomal dominant multi-system disorder, 
inflammatory myophathies and dermatomyositis. Therefore, identification of regulators that ensure 
efficient defense without harmful immune-pathology is particularly critical to deal with RIG-I-associated 
diseases. Here, we presented the inflammatory inducible FAT10 as a novel negative regulator of RIG-I-
mediated inflammatory response. In various cell lines, FAT10 protein is undetectable unless it is induced 
by pro-inflammatory cytokines. FAT10 non-covalently associated with the 2CARD domain of RIG-I, and 
inhibited viral RNA-induced IRF3 and NF-kB activation through modulating the RIG-I protein solubility. 
We further demonstrated that FAT10 was recruited to RIG-I-TRIM25 to form an inhibitory complex 
where FAT10 was stabilized by E3 ligase TRIM25. As the result, FAT10 inhibited the antiviral stress 
granules formation contains RIG-I and sequestered the active RIG-I away from the mitochondria. Our 
study presented a novel mechanism to dampen RIG-I activity. Highly accumulated FAT10 is observed 
in various cancers with pro-inflammatory environment, therefore, our finding which uncovered the 
suppressive effect of the accumulated FAT10 during virus-mediated inflammatory response may also 
provide molecular clue to understand the carcinogenesis related with infection and inflammation.
Retinoic acid inducible gene I (RIG-I) is a key cytosolic pattern recognition receptor that mediates innate immune 
responses against RNA virus infection1. Upon recognition of intracellular foreign RNAs, RIG-I undergoes a con-
formational change that exposes its CARD domain for interaction with the mitochondrial antiviral signaling 
adaptor (MAVS) on the mitochondrial outer membrane2. MAVS then triggers the activation of transcription fac-
tors IRF3/7 and NF-kB to produce type I interferons (IFNs) and pro-inflammatory cytokines, which are critical 
mediators of host cellular antiviral response3.
Strength and duration of the RIG-I mediated immune-surveillance are tightly regulated to avoid deleteri-
ous effects caused by excessive inflammatory response4. Although inflammatory cytokines produced during 
the acute infection is critical for clearing pathogens, healing and regeneration of injured tissues, the sustained 
or hyper-production of inflammatory cytokines causes auto-immune or inflammatory diseases5,6. RIG-I 
hyper-activating mutations have recently been identified in patients with Singleton-Myerten syndrome (SMS), 
an autosomal dominant multi-system disorder characterized by the presence of glaucoma, psoriasis, and aortic 
calcification7. Altered RIG-I expression has also been linked to inflammatory myophathies pathogenesis and 
dermatomyositis8. Therefore, the identification of regulators that ensure the double-edged function of RIG-I 
inflammatory response is particularly important to elucidate approaches for the prevention and treatment of 
RIG-I-associated diseases.
Ubiquitin or ubiquitination is one of the most extensively studied regulators or regulating processes of 
RIG-I mediated signaling pathway. Multiple ubiquitin E3 ligases, deubiquitinases, and ubiquitin-specific pro-
teases have been identified to particularly modulate the RIG-I-mediated immune response9. For example, tri-
partite motif protein 25 (TRIM25), an E3 ubiquitin/ISG15 ligase10, elicits RIG-I activation by inducing K63 
poly-ubiquitination11. In parallel, although not distinct from ubiquitin, the post-translational modification of 
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cellular targets by ubiquitin-like modifier (UBLs) family also owns great capacity to modulate the protein func-
tion. Members of UBLs are recognized as important regulators of RIG-I-mediated signaling in a conjugation 
dependent manner: SUMO conjugation to RIG-I enhances the IFN production via the augmentation of ubiquit-
ination and interaction with MAVS12. Atg5-Atg12 conjugates to RIG-I and MAVS and inhibits the production of 
type I IFN13, while ISG15 conjugates to RIG-I and lowers the stability of RIG-I proteins14.
HLA-F adjacent transcription 10 (FAT10), a UBL protein uniquely found in mammals, is well-known as a 
signal for proteasomal degradation15. FAT10 is involved in several cellular processes that occur via either con-
jugation to target proteins or non-covalent association with other proteins. FAT10 interacts with MAD2 to con-
trol chromosome stability and cell cycle progression16,17, while under proteasome inhibition, it associates with 
HDAC6 to be sequestered into the aggresome18. Highly accumulated FAT10 is observed in various cancers with 
pro-inflammatory environment19,20 and emerging evidences implicate FAT10 as a key regulator of inflammatory 
carcinogenesis21–23. However, FAT10 contribution in host-virus interaction, especially in the innate immunity 
against infection has not been explored.
In the presented manuscript, we demonstrated the inflammatory inducible FAT10 as a novel negative reg-
ulator of RIG-I-mediated inflammatory response. Through non-covalent association with an activated form of 
RIG-I, FAT10 sequesters it away from the signaling transmission platform and attenuates RIG-I mediated anti-
viral response.
Results
Enhanced FAT10 expression inhibits the formation of antiviral stress granules containing RIG-
I-G3BP-1. FAT10, a ubiquitin-like modifier that functions as a regulator of inflammatory carcinogenesis, is 
transiently induced under TNFα and IFNγ co-stimulation, but not in cells infected with virus alone (Fig. 1a). 
However, pro-inflammatory cytokine induction of FAT10 expression was severely reduced when virus was 
infected (Fig. 1b). In virus-infected cells, the level of FAT10 expression by cytokines was significantly reduced, 
and the concurrent co-localization of FAT10 and RIG-I was observed (Fig. 1c). It has been previously reported 
that RIG-I is present within the antiviral stress granules (avSGs) along with viral RNA and various antiviral 
proteins24,25. Indeed, endogenous RIG-I forms speckles together with GTPase activating protein (SH3 Domain) 
binding protein 1 (G3BP-1), a stress granule marker protein, in virus-infected cells (Supplementary Fig. 1a). We 
also have observed that poly I:C induction of RIG-I speckle formation was disrupted by co-treatment with TNFα 
and IFNγ (Fig. 1d). Furthermore, overexpressed FAT10 specifically blocks the formation of avSGs, which are 
normally induced by poly I:C stimulation (Fig. 1e). In cells overexpressing Flag-FAT10, G3BP-1-containing avSGs 
were only detected in 15.5% of cells; the remaining 84.5% of cells displayed no evidence of avSGs formation. 
In these cells, RIG-I and G3BP-1 were always co-localized (Supplementary Fig. 1b). These results suggest that 
enhanced FAT10 expression inhibits avSG formation and negatively influences RIG-I signaling pathway.
FAT10 overexpression inhibits RIG-I-mediated antiviral signaling pathways. To clarify the 
effect of enhanced FAT10 expression on RIG-I mediated antiviral signaling pathways, we examined the 
transactivation activity of the transcription factors interferon regulatory factor-3 (IRF3) and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) using PRD III-I and NF-kB regulatory element reporter 
assays, respectively. RIG-I-mediated activation of IRF3 and NF-kB was significantly reduced by the overexpres-
sion of exogenous Flag-FAT10, both at a basal level and after Poly I:C stimulation (Fig. 2a,b). A similar repressive 
effect of Flag-FAT10 overexpression on IRF3 activity was observed after viral infection or after stimulation with 
the RIG-I-specific agonist, 5′ ppp-dsRNA (Fig. 2c,d). Consistent with the reporter assay results, both IRF3 nuclear 
localization and phosphorylation of IRF3 were blocked by FAT10 overexpression (Fig. 2e,f). In contrast, overex-
pressed FAT10 did not alter increased PRD III-I activity following IRF3 overexpression (Fig. 2g), suggesting that 
FAT10 specifically acts upstream of IRF3 activation to attenuate RIG-I-mediated signaling pathways.
FAT10 can exert its effects through both conjugation-dependent and conjugation-independent mechanisms26. 
Using a conjugation-defective FAT10 mutant, in which an AA was substituted for GG at the FAT10 C-terminus, 
we found that covalent-conjugation of FAT10 is not required for its inhibitory effect on RIG-I mediated antiviral 
responses (Fig. 2h).
Next, we investigated whether constitutive RIG-I activity could be inhibited by FAT10 overexpression. An 
expression vector encoding the tandem caspase activation and recruitment domains (2CARD) of RIG-I was 
transfected into cells and the trans-activation activities of both IRF3 and NF-kB were measured without fur-
ther stimulation. The results showed that 2CARD-RIG-I constitutive activation was significantly reduced by 
Flag-FAT10 overexpression (Fig. 2i,j). This inhibitory effect of FAT10 on constitutive RIG-I activity was also 
independent of protein conjugation (Fig. 2k). These findings confirm that FAT10 negatively regulates the 
RIG-I-mediated anti-viral signaling pathway.
Identification of the FAT10 protein as a novel RIG-I interacting protein. Based on the 
co-localization of RIG-I and FAT10, we evaluated whether FAT10 regulates RIG-I protein via protein-protein 
interaction by investigating exogenous Flag-FAT10 and Myc-RIG-I physical interactions following trans-
fection into HEK293FT cells (Fig. 3a). Immunoprecipitation using α -Flag antibody clearly detected over-
expressed Myc-RIG-I, confirming the physical interaction of FAT10 and RIG-I proteins. Those proteins that 
were pulled down together with FAT10 were not FAT10-conjugated forms of RIG-I because their molecular 
weights were similar to those of the free forms of Myc-RIG-I observed in SDS-containing gels. Physical interac-
tion between endogenous FAT10 and RIG-I proteins was also observed in the lysates from cells stimulated with 
TNFα and IFNγ (Fig. 3b). Consistent with the effect of FAT10 on RIG-I-mediated intracellular signaling, the 
conjugation-defective FAT10 AA protein also interacted with RIG-I, confirming that FAT10 interaction with 
RIG-I is independent of its conjugation ability (Fig. 3c). Next, using a series of deletion construct, we mapped the 
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RIG-I domain responsible for FAT10 interaction (Fig. 3d). RIG-I contains various functional domain, including 
2CARD domains, Helicase domain and Repressor Domain (RD). Therefore various forms of truncated mutants, 
which contains only 2CARD domain, lacks 2CARD domain, or lacks RD domain were generated. When the 
RIG-I N-terminal 2 CARD domain was deleted, its interaction with FAT10 was abolished, whereas the 2CARD 
domain of RIG-I was sufficient to maintain their interaction (Fig. 3d). This finding is consistent with a previ-
ous observation that IRF3 activation induced by 2CARD overexpression was inhibited by FAT10 overexpression 
(Fig. 2k). Based on these data, we concluded that FAT10 associates non-covalently with RIG-I and that the RIG-I 
N-terminal 2CARD domain is essential for this interaction.
FAT10 overexpression leads to 2CARD-RIG-I precipitation as an insoluble aggregate. When 
a 2CARD-RIG-I protein was co-expressed with FAT10, we repeatedly observed that FAT10 decreased 
2CARD-RIG-I protein levels in a dose-dependent manner (Fig. 4a). Further, we investigated whether over-
expressed FAT10 alters 2CARD-RIG-I protein stability. However, treating cells with MG132 or chloroquine, 
which specifically block either classical 26S proteasome- or lysosome-dependent protein degradation pathways, 
Figure 1. FAT10 inhibits RIG-I containing antiviral stress granules (avSGs) formation. (a), HepG2 cells 
were treated with TNFα and IFNγ (20 ng/ml each) (left) or infected with SeV (right) for indicated time. (b), 
Top, After 12 h of SeV infection, TNFα and IFNγ (20 ng/ml each) were treated for indicated time. Bottom, 
After 3 h of IVA DelNS1 infection, TNFα and IFNγ (20 ng/ml each) were treated for 9 h. (c), After 3 h of SeV 
infection, TNFα and IFNγ (20 ng/ml each) were treated for 9 h. Cells were fixed and stained with α -RIG-I and 
α -FAT10 antibodies. (d), HCT116 cells were stimulated with TNFα and IFNγ (20 ng/ml each), poly I:C or 
together for 9 h. Cells were stained with α -RIG-I and α -FAT10 antibodies. (e), HepG2 cells were transfected 
with Flag-FAT10 or Flag-CMV (empty vector). After 6 h of poly I:C stimulation, cells were fixed and stained 
with α -Flag and G3BP-1 antibodies. Total 142 FAT10 -transfected cells were examined for G3BP-1 speckle 
formation.
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respectively, did not perturb the effect of overexpressed FAT10 on 2CARD-RIG-I protein concentration (Fig. 4a, 
Supplementary Fig. 2a).
Because it has been previously reported that FAT10 is found in the aggresomes18 and that it tends to pre-
cipitate in an insoluble form27, we investigated whether FAT10 directs RIG-I into an insoluble fraction via 
protein-protein interaction. To test whether overexpressed FAT10 alters the solubility of 2CARD-RIG-I proteins, 
we harvested whole cell lysates and separated the RIPA-soluble and -insoluble fractions. In every case, increas-
ing FAT10 expression decreased the soluble 2CARD-RIG-I protein present and simultaneously increased the 
concentration of FAT10 and 2CARD-RIG-I in the insoluble fraction (Fig. 4b, Supplementary Fig. 2b). However, 
Figure 2. FAT10 overexpression inhibits RIG-I mediated antiviral signaling activities. (a,b), HEK293FT 
cells were co-transfected with indicated plasmid along with PRL-TK and pLuc-PRD III-I or pLuc-NF-kB 
reporter constructs for 36 h, followed by 12 h of Poly I:C (1 μg/ml) stimulation. Dual luciferase assay and 
analysis were performed as described. (c,d), HEK293FT cells were co-transfected with indicated plasmid along 
with PRL-TK and pLuc-PRDIII-I reporter constructs for 36 h, followed by IVA DelNS1 infection for 16 h (c) or 
5′ ppp-dsRNA stimulation for 12 h. Dual luciferase assay and analysis were performed as described. (e), HepG2 
cells were transfected with Flag-FAT10 or Flag-CMV (empty vector) for 36 h, followed by Poly I:C (1 μg/ml) 
stimulation for 4 h. After fixation, the cells were stained with α -Flag and α -IRF3 antibodies. Representative 
images of cells in each sample were shown. (f), HepG2 cells were transfected with Flag-FAT10 or Flag-CMV 
(empty vector) for 36 h, followed by Poly I:C (10 μg/ml) stimulation for indicated times. Cells were harvested 
and phospho-IRF3 level was examined. (g–k), HEK293FT cells were transfected with indicated plasmids along 
with PRL-TK and pLuc-PRD III-I or pLuc NF-kB reporter constructs. Dual luciferase assay and analysis were 
performed as described. Data presented in graph was from three independent experiments, mean ± SD (error 
bar). **indicates p < 0.01.
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in whole cell lysates prepared in the Lammeli buffer, the 2CARD-RIG-I total protein concentration remained 
unchanged despite increasing levels of FAT10 overexpression (Fig. 4c). These results indicate that FAT10 did not 
alter 2CARD-RIG-I protein stability but instead simply relocated 2CARD-RIG-I from the soluble to insoluble 
fraction. Because the FAT10 overexpression suppressed 2CARD-RIG-I activity in parallel with its relocation into 
the insoluble fraction, we concluded that FAT10 inhibits 2CARD-RIG-I activity by sequestering the protein in 
the insoluble cell fraction.
Next, we examined whether FAT10 also regulates the solubility of full length RIG-I proteins. When Myc-RIG-I 
was co-overexpressed with FAT10, changes in cytosolic RIG-I protein levels were barely detectable under basal 
conditions. However, viral infection decreased amount of RIG-I protein present in the cytosol fraction and at the 
same time, increased the level of RIG-I in the insoluble fraction (Fig. 4d). Next, we examined whether changes in 
endogenous RIG-I solubility occurred. To cause excessive amounts of endogenous FAT10 accumulation, FAT10 
production was induced by exposure to high doses of TNFα and IFNγ and protein degradation was blocked by 
the 26S proteasome inhibitor MG132. Under these harsh conditions, endogenous RIG-I was observed in the 
insoluble fraction along with the FAT10 proteins (Fig. 4e). Furthermore, the amounts of insoluble RIG-I dimin-
ished when endogenous FAT10 was silenced (Fig. 4f). These data indicate that FAT10 sequesters the active form 
of RIG-I into insoluble precipitate, only when excessive amounts of FAT10 are present.
Figure 3. FAT10 physically interacts with RIG-I. (a), The physical interaction of RIG-I and FAT10 was 
examined using α -Flag immunoprecipitation of total lysate from Myc-RIG-I and Flag-FAT10 transfected 
HEK293FT cells. (b), HepG2 cells were treated with TNFα and IFNγ (50 ng/ml each) for 12 h. Total lysates were 
immunoprecipitated with α -FAT10 antibody. (c), HEK293FT cells were transfected with Myc-RIG-I and Flag-
FAT10 GG or Flag-FAT10 AA for 48 h, and physical interaction was examined by immunoprecipitation of total 
lysates with α -Flag antibody. (d), HEK293FT cells were transfected with truncated forms of Flag-RIG-I along 
with HA-FAT10 for 48 h, followed by the immunoprecipitation of total lysates with α -Flag antibody. Bands at 
55 kDa and 25 kDa are heavy and light chains of IgG.
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Because activated RIG-I undergoes a conformational change that facilitates its interaction with MAVS on 
the mitochondrial outer membrane, we determined whether altered RIG-I protein solubility influenced the 
translocation of active RIG-I into the mitochondria. Cells were co-transfected with both 2CARD-RIG-I and 
FAT10, and mitochondrial concentrations of FAT10 and 2CARD-RIG-I were measured (Supplementary Fig. 
2c,d). Results indicated that most of 2CARD-RIG-I protein detected along with mitochondrial MAVS disap-
peared when FAT10 was overexpressed. Furthermore, the overexpression of both FAT10-GG and FAT10-AA 
had a similar effect on 2CARD-RIG-I localization to the mitochondria (Fig. 4g), indicating that FAT10 moves 
activated RIG-I into the insoluble cellular compartment and prevents RIG-I from targeting the mitochondria in 
a conjugation-independent manner.
Figure 4. Overexpressed FAT10 induces activated RIG-I (2CARD) precipitation. (a), HEK293FT cells 
were transfected with indicated plasmids for 48 h. Cells were treated with 20 μM MG132. (b), HEK293FT cells 
were transfected with indicated plasmids for 48 h. After harvesting, the soluble and insoluble fractions were 
prepared using RIPA lysis buffer. The protein levels of FAT10 and CARD in each fraction were analyzed. (c), 
HEK293FT cells were transfected with indicated plasmids for 48 h, whole cell lysates were prepared in Laemmli 
buffer containing 5% β -mercaptoethanol. (d), HEK293FT cells were transfected with indicated plasmids for 
48 h, Lasota NDV was infected for 12 h before harvest. Cytosol (soluble) and insoluble fractions were prepared 
using sucrose buffer. Protein levels of FAT10 and RIG-I in each fraction were analyzed. (e), HepG2 cells were 
pre-treated with TNFα and IFNγ with final concentration (ng/ml) as indicated for 2 h following by Poly I:C 
(10 μg/ml) transfection. MG132 (20 μM) or DMSO was treated for 4 h before harvesting. Endogenous RIG-I and 
FAT10 protein levels were analyzed in the RIPA soluble and insoluble fractions. (f), same as e, except HepG2 
cells were transfected with control or FAT10 siRNA. (g), HEK293FT cells were transfected with indicated 
plasmids, and the protein levels of FAT10 and CARD were examined in the mitochondria enriched fraction.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:23377 | DOI: 10.1038/srep23377
The T55 residue in the RIG-I CARD domain is required for the interaction with FAT10. The 
sequestering effect of FAT10 on RIG-I was inevitable when the constitutive active 2CARD-RIG-I was used or 
when RIG-I was activated by viral infection. Furthermore, a natural RIG-I splicing variant (RIG-I SV) that har-
bors a short deletion within the first CARD domain failed to interact with FAT10 (Fig. 5a). RIG-I SV lost its ability 
to interact with the E3 ligase TRIM25, and as the results demonstrated, it could not initiate downstream signa-
ling28 (Fig. 5b). Therefore, to test whether active RIG-I is a selective target of FAT10 regulation, we introduced 
inactivating point mutations into 2CARD-RIG-I. A T55I mutation abolishes RIG-I interaction with TRIM25, 
whereas a K172R mutation results in the loss of K63 ubiquitination11,28. These generated mutants were inactive as 
measured by an IRF3 activation luciferase assay (Fig. 5c, upper). We also examined the presence of 2CARD-RIG-I 
and FAT10 in the soluble fraction by using lysates of the same luciferase assay (Fig. 5c, bottom). When FAT10 was 
co-expressed, both the normal and K172R mutant proteins disappeared from the soluble fraction; however, the 
T55I mutant protein remained. Indeed, the solubility of the T55I mutant protein did not change, even in the pres-
ence of high concentrations of FAT10 (Fig. 5d). Moreover, we examined whether changes in RIG-I solubility are 
dependent upon FAT10 interaction. In agreement with the observed changes in solubility, the interaction between 
T55I and FAT10 was much weaker compared with WT or K172R interactions (Fig. 5e). These results indicate that 
K63 ubiquitination of the K172 residue is not required, but that an intact RIG-I-T55 residue is required for FAT10 
interaction. This interaction appeared to be a pre-requisite for FAT10-mediated RIG-I precipitation.
TRIM25 stabilizes the FAT10 protein by inhibiting its degradation. Because the RIG-I T55 res-
idue is essential for interaction with the TRIM25 E3 ligase, it is possible that FAT10 competes with TRIM25 
for 2CARD-RIG-I binding, thereby inhibiting TRIM25-mediated RIG-I activation. Consequently, we examined 
whether FAT10 overexpression suppressed TRIM25-mediated RIG-I signaling activity (Fig. 6a). 2CARD-RIG-I 
mediated IRF3 activation was further enhanced by TRIM25 over-expression, and this enhanced activity was 
significantly reduced by FAT10 overexpression. In contrast, TRIM25 overexpression slightly altered the inhibi-
tory effect of FAT10 on 2CARD-RIG-I. Moreover, TRIM25 overexpression did not prevent 2CARD-RIG-I pre-
cipitation by FAT10 (Fig. 6b). In addition, transfected exogenous Flag-FAT10 protein levels were substantially 
enhanced by TRIM25 co-expression (Fig. 6c). FAT10 is an unstable protein with a half-life of 1 h, with its protein 
stability regulated through 26S proteasome-dependent degradation15. Interestingly, FAT10 stability was signif-
icantly enhanced by TRIM25 overexpression (Fig. 6c). After 2 h of treatment with cycloheximide, most of the 
Flag-FAT10 protein had disappeared. However, when TRIM25 was present, there was no significant decrease in 
Flag-FAT10 protein even after cycloheximide treatment. Co-transfection with V5-TRIM25 resulted in an effect 
that was similar to that with MG132 (Fig. 6d). Furthermore, when TRIM25 was silenced, endogenous FAT10 
protein stability was reduced (Fig. 6e). Collectively, these data suggest that TRIM25 stabilizes FAT10. Of note, 
Figure 5. T55 residue of RIG-I is needed to mediate interaction with FAT10. (a), HEK293FT cells were co-
transfected as indicated for 48 h, following by immunoprecipitation with α -Flag antibody. (b,c), HEK293FT 
cells were co-transfected with indicated plasmid along with PRL-TK and pLuc-PRD III-I reporter constructs 
for 48 h. Dual luciferase assay and analysis were performed as described. (d), HEK293FT cells were transfected 
with an increasing dose of Flag-FAT10 and indicated plasmids for 48 h. After harvesting, soluble and insoluble 
fractions were prepared in the passive lysis buffer. The protein levels of FAT10 and CARD WT or mutant in 
each fraction were analyzed using the indicated antibody. (e), The physical interaction of CARD mutants and 
FAT10 were examined using immunoprecipitation of total lysate from transfected HEK293FT cells with α -Flag 
antibody.
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TRIM25 was recently reported to enhance p53 stability through the inhibition of proteasomal p53 protein deg-
radation29. We propose that FAT10 is recruited to RIG-I-TRIM25 to form an inhibitory complex where FAT10 
is stabilized. As a result, stabilized FAT10 sequesters active RIG-I into an insoluble fraction that restricts RIG-I 
localization to MAVS containing mitochondria (Fig. 7).
Discussion
Our study has demonstrated how the coordinated interplay of RIG-I, TRIM25, and FAT10 regulate the antiviral 
innate inflammatory response. We have discovered a dual role of TRIM25 in the regulation of RIG-I activity. 
When a host cell detects a viral infection, TRIM25 induces unanchored K63 ubiquitination of RIG-I, thereby 
activating RIG-I antiviral defense responses. Upon the accumulation of the proinflammatory-inducible protein 
FAT10, RIG-I activity is suppressed. Because the basal FAT10 level is low and silencing basal FAT10 expression 
did not considerably affect Poly I:C induced avSGs formation (Supplementary Fig. 3a), we concluded that FAT10 
may elicit its repressive function mainly under inflammation conditions. TRIM25 also enhanced FAT10 stability, 
thereby strengthening the inhibitory effect of FAT10 to attenuate RIG-I-mediated inflammatory response, most 
likely in situations of severe inflammation.
Because of their importance in the recognition and regulation of viral infection, RLR-mediated signaling 
activities are tightly controlled by various mechanisms. For example, NLRX1 regulates RIG-I targeting to MAVS 
within the mitochondria30, NLRX5 and HSCARG regulate RIG-I downstream signal transduction31,32, and ubiq-
uitin and ISG15 regulate RIG-I protein concentration through K48 polyubiquitination and ISGylation9,14. Here we 
have presented a novel pathway for regulating RIG-I signaling activity involving altered protein solubility. It has 
been previously reported that RIG-I is found in the insoluble fraction in the HIV-1-infected monocyte-derived 
macrophages33. Furthermore, the NS proteins of SFTSVs virus have been recently shown to inhibit IFN signa-
ling through the active relocation of RLR signaling components, including the movement of RIG-I, TBK1, and 
TRIM25 to an insoluble fraction, which was described as an NS-induced cytoplasmic structure34. Therefore, 
the redistribution of RIG-I and related components may be employed by viruses as a way to overcome the host 
anti-viral response.
To date, the physiological functions of FAT10 in the innate immune response to viral infection have not been 
reported, although its potential involvement has been generally implicated. FAT10 expression is up regulated 
Figure 6. TRIM25 stabilizes FAT10 protein by inhibition of proteasomal degradation. (a), HEK293FT cells 
were co-transfected with indicated plasmid along with PRL-TK and pLuc-PRD III-I reporter constructs for 
48 h. Dual luciferase assay was performed as described. (b), HEK293FT cells were transfected with indicated 
plasmids for 48 h. After harvesting, soluble and insoluble fraction was prepared as described in RIPA lysis buffer. 
The protein levels of FAT10, TRIM25, and CARD in each fraction were analyzed using indicated antibodies. 
(c), HEK293FT cells were transfected with indicated plasmids for 36 h. After CHX (50 μg/ml) treatment for 
2 h, whole cell lysate was prepared in Laemmeli buffer. (d), HEK293FT cells were transfected with indicated 
plasmids for 36 h, and then treated with an indicated dose of MG132 for 12 h. After harvesting, soluble and 
insoluble fractions were prepared in RIPA lysis buffer. (e), HepG2 cells were transfected with TRIM25 siRNA or 
control siRNA for 36 h, and treated with TNFα and IFNγ for additional 12 h. After CHX (50 μg/ml) treatment 
for indicated time, whole cell lysate was prepared in Laemmeli buffer. Endogenous FAT10 level was examined 
(left) and silencing of TRIM25 by siRNA was confirmed by qPCR (right). Band intensity of FAT10 was 
normalized with GAPDH (left).
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during Kaposi sarcoma-associated herpesvirus infection35 and in HIV-associated neuropathy36. FAT10 interacts 
with the HIV accessory protein Vpr to mediate Vpr-induced cell death36. In addition, FAT10 functions in the 
intracellular defense against bacteria by decorating cytoplasmic Salmonella Typhimurium that has been targeted 
for xenophagy37. Furthermore, FAT10-deficient mice are more sensitive to endotoxin challenge38, and FAT10 
deletion in rats negatively affects virus-triggered autoimmune diabetes39, suggesting potential regulatory role 
of FAT10 during infection. The present study is the first to demonstrate this previously unreported function of 
FAT10 in an antiviral response. Our findings highlight the importance of controlling FAT10 to efficiently handle 
the various pathologies caused by RNA viruses. Through its ability to inhibit RIG-I, an important sensor for 
innate immunity, FAT10 ensures the precise regulation of the virus- mediated inflammatory response. However, 
during chronic infection and inflammation, the suppressive effect of accumulated FAT10 might also contribute to 
the successful establishment of a persistent infection that initiates an infection-triggered cancer.
FAT10 was previously reported to be present in the insoluble fraction27, and has also been reported to con-
jugate with polyglutamine proteins and control their solubility40. Moreover, an active LRRFIP2 adaptor pro-
tein has been reported to translocate from the membrane to the insoluble fraction in a manner that requires 
FAT10 conjugation41. Herein, we have demonstrated that overexpressed FAT10 can control protein solubility 
through the non-covalent protein-protein interaction. Endogenous FAT10 was also found in the insoluble frac-
tion, with the protein concentration in the insoluble fraction further increased by the inhibition of proteaso-
mal degradation. Endogenous RIG-I was also observed in the insoluble fraction in FAT10 dependent manner 
(Fig. 4e,f), suggesting that the insoluble RIG-I and FAT10 proteins were targeted for degradation via the protea-
some. The detergent-insoluble cell fraction concentrates chromatin, cellular structures, aggregated proteins, and 
cytoskeleton-associated proteins40,42–45. Transition from the soluble to the insoluble fraction could mean changes 
in cellular localization, protein conformation, or protein association. Proteins can be found in the insoluble frac-
tion under specific physiological conditions, such as pathological transition or infection as a result of changes in 
their biochemical properties44,46,47. A change in RIG-I protein solubility may require additional post-translational 
modifications, although this possibility remains to be investigated.
The current study and previously published reports have shown that FAT10 is both inducible and extremely 
unstable. As a result, the FAT10 protein is barely detectable in most normal, untreated cells, and it is only tran-
siently induced by inflammatory signaling17. We found that TRIM25 stabilizes FAT10 through the inhibition of its 
proteasome-dependent degradation. Recently, TRIM25 has been shown to enhance stability of p53 and mdm229, 
and TRIM25 overexpression in ovarian tumors has been reported48. Our finding that additional TRIM25 activity 
controls the stability of short-lived proteins may explain how the FAT10 protein accumulates to a high level in 
various cancers. In conjunction with its ability to counteract p53, Akt, β -catenin21–23 and chromatin stability17, 
the suppressive function of accumulated FAT10 may provide a molecular clue to help understand the associations 
between carcinogenesis, infection and inflammation.
Materials and Methods
Plasmids. Flag-RIG-I plasmid was provided by Dr. Takashi Fujita (Institute for Virus Research, Kyoto 
University) and Myc-RIG-I was made from this construct by replacing Flag tag by Myc tag. The construc-
tion of Flag-RIG-I SV (an alternatively spliced variant of RIG-I), Flag-Helicase + RD, Flag-CARD, Flag-
CARD + Helicase were described previously49,50. To generate Flag-CARD T55I and K172R, appropriate point 
mutations were introduced into Flag-CARD using the QuickChange site-directed mutagenesis kit (Stratagene). 
Plasmid information for Flag-FAT10 GG and its non-conjugating mutant Flag-FAT10 AA has been previously 
described21. HA-FAT10 was provided by Dr. Groettrup Marcus (University of Konstanz, Germany). V5-TRIM25 
was given by Dr. Jae U. Jung (University of Southern Califonia, USA). The pLuc-NF-kB was purchased from 
Figure 7. Proposed working mechanism. Upon RNA virus infection, TRIM25 mediated K63 ubiquitination 
of RIG-I is essential for RIG-I targeting to MAVS in mitochondria and transmitting downstream signaling. As 
a consequence, type I IFNs and inflammatory cytokines are produced. Under inflammatory conditions, FAT10 
protein is accumulated. FAT10 interacts with the CARD domain of RIG-I and leads to RIG-I precipitation in 
the insoluble form. FAT10 is not as stable as it is degraded via proteasome, but TRIM25 can stabilize FAT10 
and assist its accumulation. Therefore, FAT10 selectively blocks active RIG-I targeting to its signaling platform 
(mitochondria) and efficiently attenuates RIG-I inflammatory response.
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Clonetech and the pLuc-PRD III-I was given by Dr. Katherine A. Fitzgerald (University of Massachusetts, USA). 
pSG5-IRF3-HA was given by Dr. Jae Myun Lee (Yonsei University, Korea). From pcDNA3-Flag-MAVS (kindly 
given by Dr. Chen, Howard Hughes Medical Institute, USA), myc-MAVS was constructed by cloning MAVS into 
PCS2 + MT-myc empty vector. siRNAs targeting human TRIM25 and human FAT10 (Supplementary Table S1) 
were synthesized by GenePharm (Shanghai, China).
Cell culture, transfection and stimulation. HepG2 (American Type Culture Collection, Manassas, VA), 
HCT116 (provided by Dr. Bert Vogelstein, Johns Hopkins University, Baltimore, MD) and human embryonic kid-
ney HEK293FT (Life Technologies) were cultured under the recommended conditions. HepG2 cells were main-
tained in 10% FBS (Hyclone) and 1% penicillin/streptomycin (Invitrogen) containing MEM media. HEK293FT 
and HCT116 cells were maintained in 10% FBS and 1% penicillin/streptomycin containing DMEM media. For 
transient transfection in HEK293FT cells, equal quantities of expression plasmids were transfected by calcium 
phosphate method. For other cells, plasmids were transfected by Lipofectamine 2000 (Invitrogene) according 
to the manufacturer’s instruction. For agonists stimulation, indicated concentration of Poly I:C (Amersham 
Biosciences) or 5′ppp-dsRNA (Invivogen) was transfected using Lipofectamine 2000. For cytokines stimulation, 
if not specifically mentioned, 20 ng/ml TNFα or 20 ng/ml IFNγ (R&D systems, Minneapolis, MN) were applied 
to cells for indicated time. MG132, Chloroquine (Cq), and Cycloheximide (CHX) were purchased from Sigma 
(MO, US) and treated to cells as indicated. For knock down of target gene, siRNA were transfected into the cells 
using Lipofectamine 2000 (Invitrogene) according to the instruction of manufacturer.
Virus infection. IVA DelNS1 (Influenza A/PR/8/34, ΔNS1) virus was provided by Dr. Huan Huu Nguyen 
(National Vaccine Institute, Seoul, Korea). Newcastle disease virus (NDV, LaSota strain) was provided by 
National Veterinary Research Quarantine Service, South Korea and Sendai virus (SeV) was provided by Dr. P. 
Palese (Mount Sinai School of Medicine, USA). For virus infection, cells were washed with 1X PBS before treat-
ment with culture medium (mock) or indicated virus in serum-free and antibiotic free medium. After absorption 
at 37 °C for 1 h, media was changed, and cells were cultured for various periods in the serum-containing media. 
Mock indicated untreated sample.
RNA isolation and real-time quantitative RT-PCR. RNA was isolated with the RNAiso reagent (Takara, 
Shiga, Japan) according to the instructions of manufacturer. Total RNA (1μg) was reverse transcribed using the 
ImProm-II TM Reverse Transcription Kit (Promega) with Oligo dT as primer. Quantitative real-time PCR was 
performed with StepOne plus (Applied Biosystems) using SYBR-Premix Ex Taq (Takara). Primer information 
was provided (Table 1).
Immunobloting and antibodies. For immunoblotting, protein samples were separated on 12% SDS-PAGE 
and transferred to nitrocellulose membrane (Whatman, NJ). Membranes were incubated with 7% skim milk 
(in PBST 1X), followed by antibody hybridization. α -Tubulin, α -Myc, α -GFP, α -HA and goat α -RIG-I anti-
bodies were purchased from Santa Cruz Biotech. α -Mitofilin was purchased from NOVUS. α -Flag and α -V5 
were purchased from Sigma and Invitrogen respectively. α -IRF3, α -RIG-I and α -FAT10 were purchased from 
Enzo Life Science, α -phospho IRF3 (Ser369), α -G3BP-1 was purchased from Cell Signaling. α -NP antibody was 
purchased from Abcam. Immunoreactive signals were detected by enhanced chemiluminescence in horseradish 
peroxidase (Pierce Biotechnology, MA). For immunofluorescence experiments: Alexa 488-, 568-, 647- conjugated 
anti-mouse, anti-rabbit, anti-goat IgG antibody purchased from Invitrogen were used as secondary antibodies.
Immunoprecipitation. Cells were harvested in IP lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 
1% NP40, 0.5% deoxycholic acid, 0.1% SDS and 1 mM EDTA pH 8.0) with protease inhibitors (1 mM DTT, 
0.5 mM PMSF, 5 μg/ml leupeptin, 2 μg/ml pepstatin A, 5 μg/ml aprotin and 1 mM benzamindine). Total cellular 
lysates (1mg) were pre-cleared with mouse immunoglobulin G (IgG) and protein G/protein A - agarose beads 
(Calbiochem, La Jolla, CA) and then incubated with indicated antibodies (2 μg/mg of lysates) or mouse IgG 
overnight at 4 °C. After multiple 4 rounds of washing in 1 ml of IP lysis buffer, proteins were eluted by boiling at 
95 °C in laemmli buffer (Biophoretic) containing 5% β -mercaptoethanol (Sigma-Aldrich). For endogenous IP, 
β -mercaptoethanol was not added in laemmli buffer. Proteins were analyzed on SDS-polyacrylamide gels. Input 
controls consisted of 5% total cell lysates.
Luciferase reporter assay. Cells were cotransfected with pLuc-NF-kB or pLuc-PRD III-I reporter con-
struct together with pRL-TK, along with indicated plasmids. Dual luciferase reporter assay was performed 
according to the manufacturer’s instruction (Promega). Firefly luciferase activity was measured and normalized 
with the value of renilla activity. “Rel. Luc. Activity (Fold)” relative value to control sample (unstimulated, trans-
fected with empty vector and luciferase plasmids) was used. Data obtained from three independent experiments, 
mean ± SD. **indicates p < 0.01.
Immunofluorescence microscopy. Cells were fixed with 4% paraformaldehyde for 10 min, permeabilized 
with 0.2% Triton X100 in PBS for 8 min at RT, blocked with 1% goat serum in PBST for 1 h at RT, and incubated 
at 4 °C overnight with the relevant primary antibodies. After incubation with secondary antibodies at RT for 
1 hour, nuclei were stained with Hoechst 33258 (Sigma). Slides were mounted and then images were acquired 
using fluorescence microscopy (Carl Zeiss, Jena, Germany) equipped with an ApoTome (Carl Zeiss) through a 
63X oil fluorescence objective. In Supplementary Fig. 1b, images were acquired using a modified Zeiss Axiovert 
200M microscope equipped with a Photometrics Coolsnap HQ camera through a 40X objective. The scale bar 
represents 10 μm.
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Confocal microscopy and avSGs quantification. In Fig. 1c and Supplementary Fig. 3a, images were 
acquired using a Zeiss LSM 510 META confocal laser scanning microscopy through a 63X oil objective. The 
images were processed using the LSM 5 image browser and presented as pseudo images. The scale bar represents 
10 μm. % cells formed stress granules in each sample were calculated in 10 random fields (each contains 8–12 
cells). Data obtained from three independent samples, mean ± SD.
Subcellular fractionation. We used three different kinds of cell lysis buffer to harvest the soluble and insol-
uble fraction separately. For Passive lysis buffer (Promega) or RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1% NP40, 0.5% deoxycholic acid, 0.1% SDS) supplemented with protease inhibitors, cellular lysates were 
collected and centrifuged at 12,000 g, 30 min. The supernatant was collected as soluble fraction and remaining 
pellet was boiled at 95 °C in laemmli buffer containing 5% β -mercaptoethanol for 10 min, as insoluble fraction. 
For Sucrose buffer (320 nM sucrose, 10 mM Tris-Cl pH 8.0, 3 mM CaCl2, 2 mM MgOAc, 0.1 mM EDTA, 0.5% 
NP-40, with protease inhibitors), cells lysates were harvested after centrifugation at 600 g. The cytosol (superna-
tant) was collected, and the pellet was washed with sucrose buffer without NP40 and boiled at 95 °C in laemmli 
buffer containing 5% β -mercaptoethanol to prepare insoluble fraction.
Mitochondrial/cytosol fractionation. Harvested cells were washed in 1X PBS, suspended in a mito-
chondria isolation buffer (250 mM sucrose, 1 mM EGTA, 1 mM MgCl2, 0.5 mM DTT, 10 mM Tris-Cl pH 8.0, 
EDTA-free protease inhibitors), and disrupted by dounce homogenization. The homogenate was centrifuged at 
800 g for 10 min. The supernatant was harvested and centrifugated 8,000 g for 10 min. The resulting pellet was col-
lected as mitochondria fraction while the supernatant (cytosolic fraction) was cleared by further centrifugation 
for 30 min at 12,000 g before harvesting. GAPDH was used as the marker of the cytosolic fraction and Mitofilin 
was used as the marker of the mitochondrial fraction.
Statistical Analysis. Statistical analyses were performed by two-tailed Student’s t test. P < 0.05 was consid-
ered statistically significantly different.
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